'The lower level of anticipated sales to Stryker in 2008 is clearly disappointing but we, as does Stryker, remain confident that the potential for Cormet in the world's largest orthopaedic market is substantial.'

This was 600p at one stage, started falling and then after the above statement. I recall that a broker downgraded target price to 300p.

Cheap at 160p?

have gone LONG on this since no profit/potential/bid priced in

intra-day reversal in progress

:-)

OXB, GWP, PRM all doing well today, SN. announced bumper results and looking strong

CRG alot of catching up, don't forget this quality stock

just starting to move now...

results out in less than 2 weeks...

worth thinking about Corin's products and the value in their intellectual property, market penetration and FDA approvals. This is a business with high barriers to entry...DYOR

don't forget these are a possible takeover target, their distributor has already shown interest in them...L2 getting stronger

edging higher

Corin Group PLC (LSE: CRG), a leading manufacturer and supplier of orthopaedic devices, will publish its Interim Results for the six months ended 30 June 2008, on Thursday, 28 August 2008.

Watch this space...this will rocket, when it becomes clear that things are improving, recently there were rumours of takeover and rumour of tie-up - DYOR.

poised to move northwards

SS been following some of your comments on stocks, impressive.

Advise a read of the Interim Management System 14/5 and then you will appreciate how oversold this share really is. Analysts reduced their target to 300p back then, incredibly cheap now.

Results out in 8 trading days.

Look at SN. to see how well the sector is performing.

Extracted from a recent update from SN. 'Smith & Nephew's results follow a strong quarter of growth from rivals such as U.S.-based Stryker Corp and Switzerland's Synthes .'

All bodes very well for CRG as the recovery takes shape. Don' forget that Stryker have been targetting a takeover of CRG. Even, in the absence of a bid, an analyst was valuing these at 300p. Their FDA approval and products are worth more than this current SP reflects. DYOR

just a matter of time before the SP reacts northwards IMHO (SN. still going higher)

SN. should think about buying CRG, since both of them have FDA approval and CRG have a distribution deal with Stryker, so this will just give them another notch up in the sector. CRG undervalued, even with US sales not expected to be above 10M, the overall revenue situation is still positive and strong compared to pre-cormet and the SP was higher back then. The market will realise eventually, most likely when you run a ruler over the numbers next week, prompting upgrades and then all the buyers will come flooding in.

rising on such a red day...excellent time to buy in before the rise is vertical

start your engines...enjoy the ride :-)

minimum downside IMHO, look at the chart for all the upside and that recent spike towards 180p

position 22 on the Top % gainers list

should get even more attention tomorrow

from the news at 15:31 from moneyam 'Turning to the upside, Smith & Nephew was the top riser, up almost 3 percent, or 18 pence, at 636-1/2 after traders noted revived speculation that the orthopaedics firm could be a bid target for U.S. peer Zimmer Holdings Inc.'

CRG in the same sector, could be taken out on the cheap at say 300p - yes over double the current price! Remember an Analyst valued them at 300p if not a bid target! Cheap to say the least at the current SP IMHO

Please DYOR.

expecting an even larger rise than 7% tomorrow

from Ft.com 'Smith & Nephew was the day's main speculative feature on a revival of gossip that it could be a takeover target for Zimmer, its US orthopaedics peer.

Analysts saw some logic to the tale. S&N's hip resurfacing system would fill a gap for Zimmer, which last month delayed its rival product. S&N's latest results provided clarity about the possible cost of an investigation into its Plus division. Its shares rose 2.2 per cent to 632p, but bankers doubted contact had been made.'

Hello - Zimmer have a look at CRG, undervalued!